key: cord-0836503-fnim10e5
authors: Ankerhold, Jakob; Giese, Sebastian; Kolb, Philipp; Maul-Pavicic, Andrea; Voll, Reinhard E.; Göppert, Nathalie; Ciminski, Kevin; Kreutz, Clemens; Lother, Achim; Salzer, Ulrich; Bildl, Wolfgang; Welsink, Tim; Morgenthaler, Nils G.; Grawitz, Andrea Busse; Huzly, Daniela; Schwemmle, Martin; Hengel, Hartmut; Falcone, Valeria
title: Circulating multimeric immune complexes drive immunopathology in COVID-19
date: 2021-09-09
journal: bioRxiv
DOI: 10.1101/2021.06.25.449893
sha: 0a6c1bd1da6bfa0966d2c1ec846089f3b1ba076f
doc_id: 836503
cord_uid: fnim10e5

A dysregulated immune response with high levels of SARS-CoV-2 specific IgG antibodies characterizes patients with severe or critical COVID-19. Although a robust IgG response is traditionally considered to be protective, excessive triggering of activating Fc-gamma-receptors (FcγRs) could be detrimental and cause immunopathology. Here, we document that patients who develop soluble circulating IgG immune complexes (sICs) during infection are subject to enhanced immunopathology driven by FcγR activation. Utilizing cell-based reporter systems we provide evidence that sICs are predominantly formed prior to a specific humoral response against SARS-CoV-2. sIC formation, together with increased afucosylation of SARS-CoV-2 specific IgG eventually leads to an enhanced CD16 (FcγRIII) activation of immune cells reaching activation levels comparable active systemic lupus erythematosus (SLE) disease. Our data suggest a vicious cycle of escalating immunopathology driven by an early formation of sICs in predisposed patients. These findings reconcile the seemingly paradoxical findings of high antiviral IgG responses and systemic immune dysregulation in severe COVID-19. Clinical implications The identification of sICs as drivers of an escalating immunopathology in predisposed patients opens new avenues regarding intervention strategies to alleviate critical COVID-19 progression. Graphical abstract A vicious cycle of immunopathology in COVID-19 patients is driven by soluble multimeric immune complexes (sICs). SARS-CoV-2 infection triggers sIC formation in prone individuals. Activation of FcγRIII/CD16 expressing immune cells by sICs precedes a humoral response to SARS-CoV2 infection. sICs and infection add to IgG afucosylation, further enhancing FcγRIII/CD16 activation by opsonized targets. High inflammation induces further sIC mediated immune cell activation ultimately leading to an escalating immunopathology.

supplemented with 10% (vol/vol) FCS, sodium pyruvate (1x, Gibco), 100 U/ml penicillin-163

Streptomycin (Gibco) β-mercaptoethanol (0.1 mM, Gibco). Cells were cultured at 37°C, 5% 164 CO2. All cell lines were routinely tested for mycoplasma. 165 166

Monitoring of antibody response to SARS-CoV-2 by ELISA 167

Serum IgG antibody titers targeting S1-and N-SARS-CoV-2 proteins were measured using 168 commercial enzyme-linked immunosorbent assay (ELISA). Anti-S1-SARS-CoV-2 IgG was 169 measured by the anti-SARS-CoV-2 ELISA (IgG) Euroimmune Kit (Euroimmune, Lübeck, 170

Germany) according to manufacturer's protocol. Results, expressed as arbitrary units (AU), 171

were evaluated semi-quantitatively by calculation of the ratio of the extinction of the control or 172 patient sample over the extinction of the calibrator. This ratio is interpreted as follows: < 0.8 173 negative; ≥ 0.8 to <1.0 borderline; ≥ 1.1 positive. Anti-N SARS-CoV-2 IgG was detected using 174 the recomWell SARS-CoV-2 IgG Kit (Mikrogen Diagnostik GmbH, Neuried, Germany) 175 according to manufacturer's protocol. The corresponding antibody activity expressed in AU/ml 176 is calculated using the formula (absorbance of sample / absorbance of cut-off) × 20. Results are 177 interpreted as follow: < 20 negative; ≥ 20 to < 24 borderline; > 24 positive. IgG against the 178 SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD) were detected using 179 SARS-CoV-2 IgG ELISA Reagent Set, kindly provided by InVivo (InVivo Biotech Services  180 GmbH, Hennigsdorf, Germany) according to manufacturer's protocol. 181 182

Fcγ receptor activation assay 183

FcγRIIIA (CD16A, 158V) activation was measured by a cell-based assay as previously 184

described (42) . For detection of anti-S and anti-RBD-specific FcγR activation we utilized 185 SARS-CoV-2-S-and RBD-coated plates (kindly provided by InVivo Biotech Services GmbH, 186

Hennigsdorf, Germany). The recombinant (S)-protein was produced under serum-free 187 conditions in mammalian cells and contains amino acid residues 1 to 1213 of the SARS-CoV-188 2 Wuhan-Hu-1-isolate (GenBank annotation QHD43416.1). The furin cleavage site was 189 mutated, two mutations for protein stabilization were included, and the C-terminal domain was 190

replaced by a T4 trimerization sequence and a C-terminal hexa-His-Tag (43 Purification of SARS-CoV2-S and -N specific antibodies from serum 211 SARS-CoV-2-specific antibodies were purified using SARS-CoV-2 spike protein (S)-coated 212 plates (kindly provided by InVivo BioTech Services) and -nucleocapsid (N) -coated plates 213 recomWell SARS-CoV-2 IgG (Mikrogen Diagnostik GmbH, Neuried, Germany). Patient sera 214 were diluted 1:5 in 100 µl (two wells per serum sample) and incubated for one hour at 37°C 215 with the S-and N-precoated plates. After washing using PBS-T (0.05% Tween 20) 100 mM 216 formic acid (30 µl/well) was added and incubated for 5 min on an orbital shaker at room 217 temperature (RT) to elute bound IgG. Following pH neutralization using TRIS buffer (1 M), 218 the eluates were either directly processed or stored at 4°C. 219 220

Quantitation of antigen-specific IgG amount 221

In order to determine the relative S1-and N-SARS-CoV-2 specific IgG antibody concentration 222 of the generated eluates, S1-and N-ELISA were performed by the anti-SARS- Entringen, Germany; flow rate: 300 nL/min). For sample injection and multi-step gradient 289 formation (eluent "A": 0.5% acetic acid in water; eluent "B": 0.5% acetic acid in 80% 290 acetonitrile / 20% water; gradient length / acquisition time: 100 min or 175 min) an UltiMate 291 3000 RSLCnano system (Thermo Fisher Scientific GmbH, Dreieich, Germany) was used. 292

Eluting peptides were electrosprayed at 2.3 kV via a Nanospray Flex ion source into a Q 293

Exactive HF-X hybrid quadrupole-orbitrap mass spectrometer (both Thermo Fisher Scientific  294 GmbH, Dreieich, Germany) and analyzed by data-dependent acquisition with HCD (higher 295 energy collisional dissociation) fragmentation of doubly, triply and quadruply charged ions 296

(loop count and dynamic exclusion dependent on the gradient length). Peak lists were generated 297

with ProteoWizard msConvert (http://proteowizard.sourceforge.net/; version 3.0.11098), linear 298

shift mass recalibrated (after a preliminary database search) using software developed in-house 299 and searched against a database containing the SARS-CoV-2 UniProtKB reference proteome 300 (proteome ID: UP000464024), all human UniProtKB/Swiss-Prot entries, and optionally (to 301 reduce the number of incorrectly assigned matches) selected bacterial proteins (finally the 302

Pseudomonas fluorescens (strain SBW25) reference proteome; proteome ID: UP000002332) 303

with Mascot 2.6.2 (Matrix Science Ltd, London, UK; peptide mass tolerance: ± 5 ppm; 304 fragment mass tolerance: ± 20 mmu; one missed trypsin cleavage and common variable 305 modifications allowed). 306 307

Neutralization assay 308

Serum neutralization capacity was analyzed as previously described (46) Kinetics of IgG antibody responses following symptom onset across severe and critical 382 courses of disease. 383

It has been observed that elevated SARS-CoV-2 antibody titers are associated with disease 384 severity (15) and speculated to play a role not only in the clearance but also in the pathogenesis 385 of SARS-CoV-2 infection (47). We initially analyzed the levels and kinetics of SARS-CoV-2 386 specific IgG in serial serum samples from patients hospitalized with critical (n=27) or severe 387 (n=14) illness, a setting we also used in the following experiments. A total of 125 (critically 388 diseased) and 79 (severely diseased) serum samples, obtained from the aforementioned patients 389 at different time points within 6-25 days following symptom onset were analyzed by 390 commercially available S1-and N-specific ELISA-based assays. Assay specificity was 391 confirmed analyzing healthy donor (HD) serum samples (n=30) as negative control ( significantly earlier than anti-S1 IgG (12.5 days ± 3.3 days vs 10.6 ± 3.8; p= 0.0091). A trend 398 towards earlier seroconversion for anti-S1 IgG could be observed in critically diseased patients 399

(mean time of seroconversion 11.4 ± 3.0 days in critically diseased patients vs 12.9 ± 3.8 days 400

for severely diseased patients; p = 0.24), whereas time of seroconversion for anti-N IgG was 401 similar in both groups (10.1 ± 3.2 and 10.4 ± 4.2 days for critically and severely diseased 402 patients, respectively; p = 0.83). S1-and N-specific IgG levels at plateau did not significantly 403 differ between the two groups. No significant difference between deceased and discharged 404 patients was measured 13-25 days after symptom onset (Figure 1 -figure supplement 1 C, D, 405 E). Next, we evaluated and compared the neutralizing capacity of SARS-CoV-2 antibodies in 406 either critically versus severely diseased patients in a plaque-reduction assay (Figure 1 C) . All 407 patients mounted a robust neutralizing antibody response (91% ± 10.5 % neutralization at a 408 1:64 serum dilution), with peaking titers at 18-20 days following symptom onset. Of note, two 409 critically diseased patients developed a neutralizing response already at 6-8 days after symptom 410

onset. In summary, we observed only minor differences in cohort wide kinetics of S1-or N-411 specific IgG levels between patients hospitalized with severe or critical clinical courses 412

indicating that antibody levels per se did not correlate with severity of disease in our study. lines represent cut-off values for commercial S1-and N-specific ELISA assays. hypothesized that an exaggerated FcγR mediated activation triggered by SARS-CoV-2 specific 440

IgG might contribute to the exacerbation of COVID-19 in severely compared to critically 441 diseased patients. To address this, we analyzed the ability of SARS-CoV-2 specific antibodies 442

to activate CD16 (158V) using a previously validated cell-based reporter system (40-42, 49, 443 50) (Figure 2-figure supplement 1A) . Considering the typically late time point of health 444 deterioration, we performed an analysis of CD16 activation triggered by SARS-CoV-2 specific 445

IgG with serum samples obtained 13-25 days following symptom onset (Figure 2 ). Sera were 446

analyzed at a 1:500 dilution to stay within the dynamic range of detection ( Figure 2 - figure  447 supplement 2). Depending on the availability of sample material 2-8 samples/patient/time-point 448

were included in this analysis. If available in sufficient quantity, sera were reanalyzed. 449

Reproducibility was tested using available serum surplus ( Significant differences over all three groups were tested by ANOVA and pairwise group 482 comparison was made by Games-Howell post-hoc tests (***, p<0.001; **, p<0.01; *, p<0.05). 483 484

Based on the findings described above we speculated that differences in Fcγ mediated effector 487 functions might contribute to disease severity of COVID-19. We compared CD16 high-versus 488 CD16 low-activating patient sera regarding their SARS-CoV-2 specific IgG core fucosylation. 489

Inspired by previous findings (51-53) we focused on determining IgG core fucosylation of S-490 and N-specific SARS-CoV2 IgG. To determine IgG core fucosylation we used a lectin-based 491 ELISA preceded by antigen-specific antibody purification from immobilized SARS-CoV-2-492

antigen. Analysis of anti-S and anti-N IgG core fucosylation was performed on serum pools 493 containing five sera of either critically or severely diseased patients obtained 13-25 days post 494 symptom onset. Given the aforementioned heterogeneity in CD16-activation, we analyzed 495 pools of 5 sera of either critically or severely diseased patients characterized by either high or 496 low CD16-activation. To stay within the dynamic detection range, relative fucosylation was 497 analyzed at a dilution of 1:4 ( Figure 3 ). When analyzing serum pools from critically and 498 severely diseased patients we determined a significantly lower level of core fucosylation among 499 the high CD16 activators (Figure 3 , plain-colored bars) compared to the low CD16 activators 500 ( experiments is depicted. Statistical tests using a two-factorial linear model indicate three 518 significant differences between the low and high categories (***, p<0.001; **, p<0.01; *, 519 p<0.05; ns = not significant). 520 521

IgG complexes. 523

Next to afucosylation, it has been proposed that uncleared antigen-antibody immune complexes 524

(ICs) might be involved in the pathogenesis of severe COVID-19. (34-36, 38) . However, the 525 actual presence of circulating, multimeric soluble ICs (sICs) in critically or severely diseased 526 patients has not been shown yet. As extensive FcγR activation by sICs might contribute to the 527 severe systemic inflammatory state occurring in some COVID-19 patients with prolonged 528 disease, we surmised that sICs might be a putative explanation for the marked differences in 529 IL-6, PCT and CRP levels between critically and severely diseased patients (Table 1) . We thus 530 set out to characterize our patient cohort regarding the presence of sICs in serum samples taken 531 at various time points during disease and after hospitalization. To this end, we deployed a novel 532

cell-based reporter assay developed to quantify CD16 (158V) activation by IgG-containing 533 sICs, measuring their bioactivity (25, 44). This assay does not react to monomeric IgG or small 534 dimeric complexes in solution, but specifically identifies multimeric sICs and has been 535 successfully used to detect sICs in patients with systemic lupus erythematosus (SLE). In SLE, 536

sICs are major driver of inflammation (24). This assay showed, as judged by conventional 537 biomarkers, that sIC bioactivity correlates with SLE disease severity. Moreover, the assay is 538 sensitive to sICs size with larger complexes leading to stronger receptor activation compared 539

to small complexes (25). Analysis of serum samples, obtained 13-25 days after symptom onset, 540

revealed the presence of highly CD16-reactive sICs in SARS-CoV-2 infected patients 541 compared to healthy individuals ( Figure 4A ). Next, we compared sIC-mediated CD16 542 activation between COVID-19 patients of varying disease severity. While all COVID-19 543 patient groups tested positive for reactive sICs compared to healthy control (HD) sera, we found 544 that critically diseased patients show a striking increase in reactive sICs compared to patients 545 with severe or mild disease ( Figure 4B ). We then compared sIC bioactivity between sera from 546 critically diseased COVID-19 patients and sera from SLE patients with active disease (Figure  547 4C). We conclude that sICs formed in COVID-19 are comparable to sICs formed during active 548 SLE regarding their potential to drive inflammation. Only 6 out of 27 patients with critical 549 disease (22%) showed no sIC-mediated CD16 activation. As we did not detect highly reactive 550 sICs in the serum of 47 patients with acute respiratory distress syndrome (ARDS; mean age 551 57.5 years) in response to infections of different etiology including CMV reactivation, 552

HIV/AIDS, influenza or pulmonary TBC infection, we conclude that the formation of reactive 553 sICs is associated with severe SARS-CoV-2 disease (Figure 4-figure supplement 1 ). 554

Remarkably, longitudinal analysis of reactive sICs in the serum of critically or severely diseased 555 patients revealed high CD16 activation levels in 4 critically diseased patients already 6 to 8 556 days after symptom onset ( Figure 4D ). Of note, 2 of 4 patients with an early increase of 557 circulating reactive sIC eventually died. sIC-mediated CD16 activation persisted in 14 of 19 558 critically diseased patients at high levels until day 26 after symptom onset. sIC-mediated CD16 559 activation in severely diseased patients was slightly delayed compared to critically diseased 560 patients and was first detected in 4 patients 9-11 days after symptom onset ( Figure 4D ). Only 4 561 of 14 patients with severe disease showed detectable sIC-mediated CD16 activation. To verify 562 that sICs represent the CD16-reactive component in the serum of COVID-19 patients, we 563 analyzed serum-mediated CD16 activation before and after PEG8000-precipitation. This 564 treatment was previously shown to selectively precipitate large IgG complexes from solution 565

(25, 55). For this analysis, pools of 8 sera, showing either high (IC+) or no (IC-) CD16 566 activation, were compared. Sera from healthy donors (HD) served as a negative control. 567

Compatible with the hypothesis of serum-derived sICs driving CD16 activation, no activation 568 was observed following incubation with 3.5% PEG8000 (Figure 4-figure supplement 2 A) . To 569 ensure that the treatment did not precipitate monomeric IgG, we tested the depleted sera for 570 remaining S1-and N-specific IgG. As depicted S1-and N-specific IgG could still be detected 571 at unchanged high levels in samples treated with 3.5% PEG8000 (Figure 4-figure supplement  572 2 B). When resolving sIC-mediated CD16 activation over the complete time of hospitalization 573 for select patients from which samples at different time points were available, we observed that 574 sIC reactivity predominantly precedes anti-S1 IgG in ELISA as well as CD16 activation by 575 SARS-CoV-2-specific IgG (Fig. 4-figure supplement 3, Fig. 4-figure supplement 5) . This 576 implies that sIC formation does not depend on the presence of SARS-CoV-2 antigens. 577 Accordingly, we were not able to identify any SARS-CoV-2-derived antigens in PEG8000-578 precipitated sICs using tandem mass spectrometry (data not shown). To further exclude the 579 formation of multimeric sICs formed from circulating S1 antigen, we also specifically targeted 580 S1 for precipitation from patient serum using biotinylated S1-specific monoclonal antibodies. 581

However and in line with our previous approach, S1-specific precipitation using streptavidin-582 sepharose beads and subsequent mass spectrometry analysis for any SARS-CoV-2-specific 583 antigens in sICs remained without result (data not shown). Recently, the role of neutrophil 584 mediated intravascular NETosis was reported to play a critical role in thrombose formation and 585 subsequent organ damage observed in severe clinical forms of COVID-19 (56-58). Since this 586 process could mediate the formation of aggregated IgG as a form of sICs, we next tested 587

whether Benzonase® nuclease treatment of patient serum would dissolve reactive sICs. To this 588 end we tested sera from critically diseased patients or healthy individuals and compared CD16 589 reactivity before and after nuclease treatment (Figure 4-figure supplement 4) . Nuclease activity 590 in diluted human serum was controlled using plasmid DNA for reference. This revealed that 591 nucleic acid was not involved in the formation of CD16-reactive sICs in critically diseased 592

patients. Finally, we tested pooled patient sera for autoantibodies against a panel of prototypical 593

autoantigens associated with autoimmune disease including anti-nuclear autoantibodies However, no significant autoantibody titers could be detected in any sera pool (data not shown). 599

Although we were not able to identify their origin, our data clearly indicates the presence of 600 circulating sICs in COVID-19 patients with an increase in CD16-reactive sICs corresponding 601 with severity of disease and reaching activation levels comparable to those observed in SLE 602 patients with active disease. Accordingly, we conclude that circulating sICs are a hitherto 603

unknown, yet contributing factor to COVID-19 disease severity and, regarding infectious 604 diseases, our findings represent an observation unique to severely diseased COVID-19 patients. outcome. We also find that patients show a wide range of sIC reactivity. According to the 685

Heidelberger-Kendall precipitation curve (69), sIC size is critically dependent on the 686 antigen:antibody stoichiometry. As the used FcγR activation assay is highly sensitive to sIC 687 size (25), it is likely that this also plays a role when detecting this bioactivity in COVID-19 688 patient serum. Therefore, we propose that in addition to the presence of sICs, the size of sICs 689 plays a role in CD16 driven COVID-19 immunopathology. Based on these findings, together 690

with the higher levels of afucosylation, we conclude that CD16 activation in COVID-19 disease 691

is governed by sIC formation and IgG glycan profiles ( Figure 5) for autoimmune diseases (71). Therefore, our findings provide an explanation for the sustained 700

immunopathology following SARS-CoV-2 infection observed in some patients as well as for 701

the efficacy of IVIg treatment in severe to critical COVID-19 disease. Finally, when we 702 analyzed sera from COVID-19 patients obtained during the following waves of the pandemic, 703

we again found comparable levels of reactive sICs in the serum of critically diseased patients 704 (data not shown) implying that sIC formation in COVID-19 is conserved across different 705 SARS-CoV-2 strains. It will be important to investigate whether such sICs may persist in 706 reconvalescent patients and might be an explanation for immune alterations including auto-707 antibodies observed in patients with persistent long COVID-19 symptoms (72). Longitudinal changes in anti-SARS-CoV-2 IgG titers in severely and critically diseased 958 patients.

Serial serum samples were collected from hospitalized COVID-19 patients and used for SARS-960

CoV-2-specific IgG measurement. IgG responses against SARS-CoV-2 S1-and N-protein in 961

(A, C) critically (red symbols) and (B, D) severely (blue symbols) diseased patients. Dotted 962 lines represent cut-off values for commercial S1-and N-specific ELISA assays. Each symbol 963

represents the mean value of all samples which were available for each patient at the indicated 964 time range after symptom onset. There are no significant t-tests (i.e. p>0.05 for all 965 comparisons). 966 967 Cell-based reporter assay measuring CD16 activation in response to immobilized IgG and 972 sICs.

BW5147 reporter cells expressing chimeric human FcγRIII secrete IL-2 in response to FcγR 974 activation by A) clustered viral specific IgG binding solid-phase antigen or B) soluble ICs. 975

Solubility of sICs is achieved by pre-blocking an ELISA plate with PBS supplemented with 976 10% FCS as previously described (25, 44). 977 978 Dose dependent CD16 activation by SARS-CoV-2 specific IgG. 984 CD16 activation by A) S-, B) N-and C) RBD-specific IgG in 9 representatively selected serum 985 samples and one SARS-CoV-2 negative serum (dark blue bars). Sera were serially diluted at 986 1:20, 1:100, 1:500 and 1:2500. FcγRIII activation initiates IL-2 secretion by reporter cells, 987

which is subsequently measured via ELISA (OD 450 nm). Based on this empirical pretesting 988 all sera were thereafter tested at 1:100 and 1:500 dilutions to reach an optimal dynamic range 989 of response. The OD values obtained by the 1:500 dilutions were used for subsequent data 990 analysis. 991 992

We thank Hans-Martin Jäck for providing TRES-1-224.2.19 and TRES-II-480 728 monoclonal antibodies and Quinnlan David for critically reading the manuscript

Andreas Schlosser for validation of our Mass Spectrometry data. 730 731 Author contribution 732 Conceived and designed the experiments

736 Writing and original draft preparation

A Novel Coronavirus from Patients with 743 Pneumonia in China

An interactive web-based dashboard to track COVID-19 in real time

Clinical and immunological features of 747 severe and moderate coronavirus disease 2019

Factors associated 749 with hospital admission and critical illness among 5279 people with coronavirus disease

York City: prospective cohort study

Clinical features of patients infected with 2019 752 novel coronavirus in Wuhan

The laboratory tests and host immunity 754 of COVID-19 patients with different severity of illness

COVID-19: Immunology and treatment 756 options

Distress Syndrome and Death in Patients With Coronavirus Disease

Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 762 2019

Correction to: Clinical predictors of mortality due to 764

COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical course and risk factors for mortality of adult 767 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical course and outcomes of critically ill patients 770 with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective

Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the 774

Pathogenic T-cells and inflammatory 776 monocytes incite inflammatory storms in severe COVID-19 patients

Antibody responses to SARS-CoV-2 in 779 patients with COVID-19

Reduction and Functional Exhaustion of T 781 Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Cytokines, inflammation, and pain

Control of cytokine production by human 784 fc gamma receptors: implications for pathogen defense and autoimmunity

Characterization of functional surface 786 structures on human natural killer cells

Activation of cloned 788 human natural killer cells via Fc gamma RIII

Mouse and human FcR effector functions

Circulating and intra-792 articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding 793 activity with clinical and biological features of the disease

Role of circulating soluble immune complexes in disease

Serum immune complexes and disease activity in lupus 797 nephritis

FcγR responses to soluble 799 immune complexes are governed by solubility and size

Immune complexes: not just an innocent bystander in chronic viral 801 infection

Disease activity in systemic lupus 803 erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and 804 costimulatory molecules on dendritic cells

Receptor Gene Copy Numbers Associated With Malaria Phenotypes

420-2. 809 30. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and 810 consequences of cytokine storm and immunopathology

Exacerbated 813 innate host response to SARS-CoV in aged non-human primates

Early upregulation of 815 acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse 816 model of severe acute respiratory syndrome coronavirus infection

High titers and 818 low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

Type 3 hypersensitivity in 821 COVID-19 vasculitis

High COVID-19 virus replication rates, the creation of antigen-antibody immune 823 complexes and indirect haemagglutination resulting in thrombosis

Antibodies in Patients with Covid-19

COVID-19 inflammation with activation of the C5a-C5aR1 axis

COVID-19 as an Immune Complex Hypersensitivity in Antigen Excess Conditions

Theoretical Pathogenetic Process and Suggestions for Potential Therapeutic Interventions

Complexes May Contribute to Neutrophil Activation in the Course of 834

Severe Coronavirus Disease

Functional Characterization of a Novel Fc Gamma-Binding Glycoprotein in Rhesus Cytomegalovirus

A 842 novel assay for detecting virus-specific antibodies triggering activation of Fe gamma receptors

A 845 serological assay to detect SARS-CoV-2 seroconversion in humans

JAK inhibition prevents 847 the induction of pro-inflammatory HLA-DR(+) CD90(+) RA synovial fibroblasts by IFN

Use of mass spectrometry to study signaling pathways

Infection in Children and Their Parents in Southwest Germany

Dissecting antibody-mediated protection against SARS-CoV-2

Beyond binding: antibody effector functions in 856 infectious diseases

Identification of the first cases of complete CD16A deficiency: Association with persistent EBV 859 infection

Highly 861 individual patterns of virus-immune IgG effector responses in humans. Medical microbiology and 862 immunology

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by 866 alveolar macrophages

Afucosylated IgG 868 characterizes enveloped viral responses and correlates with COVID-19 severity

Modulating IgG effector function 871 by Fc glycan engineering

Detection of antibodies and soluble antigen-874 antibody complexes by precipitation with polyethylene glycol

CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Neutrophil extracellular traps 878 in COVID-19

Endothelial 880 dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

Ultra-Sensitive Serial 883 Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in 884 COVID-19 Patients with Severe Disease

N-protein presents early 886 in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection

The 889 model of circulating immune complexes and interleukin-6 improves the prediction of disease activity 890 in systemic lupus erythematosus

Extrafollicular 892 B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Diverse functional autoantibodies in 895 patients with COVID-19

Prothrombotic autoantibodies in 897 serum from patients hospitalized with COVID-19

Autoantibodies in Hospitalized Patients with COVID-19. medRxiv. 2021

Autoantibodies 901 against type I IFNs in patients with life-threatening COVID-19

Soluble immune complexes in human disease

Systemic lupus erythematosus: prototype of 905 immune complex nephritis in man

A Quantitative Study of the Precipitin Reaction between Type Iii 907

Pneumococcus Polysaccharide and Purified Homologous Antibody

Shock A, Humphreys D, Nimmerjahn F. Dissecting the mechanism of action of intravenous 912 immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting 913 Fcgamma receptors

Functional 915 autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 916 symptoms

Figure 2-figure supplement 4. 1005 1006 1007 Correlation of CD16 activation by virus specific IgG and ELISA levels

Pearson's correlation coefficient was used to assess the relationship between virus-specific IgG 1009 levels and their capability to trigger CD16 activation on BW5147 reporter cells in 22 paired 1010 samples from patients with critical disease (red symbols), 14 paired samples from patients with 1011 severe disease (blue symbols) and 28 samples from patients with mild disease

Each dot represents the mean value obtained by the analysis of all samples available at the 1013 indicated time points

Figure 4-figure supplement 1. 1016 1017 1018 1019 1020 CD16 activation by sICs in non-COVID-19 patients with ARDS

FcγR 1023 activation is shown as log2 fold change relative to negative control. Each symbol represents one 1024 sample from one patient. CMV: Cytomegalovirus reactivation under immunosuppression; HIV: 1025 HIV infection; TBC: Mycobacterium tuberculosis infection; Influenza: influenza virus 1026 infection; TX: solid organ transplantation

Figure 4-figure supplement 2. 1029 1030 1031 1032 PEG precipitation eliminates sIC-mediated CD16 activation

Pools of 8 sera were incubated with equal volumes of PEG8000 to reach the indicated final 1034 PEG concentrations. A) CD16 activation after PEG-precipitation in the pool supernatant, 1035 showing either high (sICs+) or no (sICs-) CD16 activation. Sera from healthy donors (HD) 1036 were included as a negative control. Activation levels are expressed as IL-2 levels (OD 450 nm) 1037 released by reporter cells. The mean and SD of two independent experiments is depicted

CoV-2 IgG levels against S1 (left panel) or N (right panel) IgG following PEG 1039 precipitation. The mean and SD of two independent experiments (sICs+/sICs-) is depicted

Figure 4-figure supplement 3

Individual sera from either critically (n = 27) or severely (n = 14) diseased patients were 1045 analyzed via ELISA [AU] for anti S1-IgG (upper row) and for CD16 activation by soluble 1046 immune complexes (lower row, relative CD16 activation depicted as fold increase to the 1047 negative control) over time (1-40 days post symptom onset

1050 1051 1052 1053 1054 Benzonase treatment of sIC-reactive sera does not abolish CD16 activation. 1055 Left panel: sIC-mediated CD16 reactivity expressed as log2 fold increase to the negative 1056 control, in serum of six individual patients before and after treatment with

M: 1058 1kb DNA ladder, Lane 1: benzonase digestion in the presence of human serum, lane 2: plasmid 1059 DNA w/o benzonase in the presence of human serum, lane 3: benzonase digestion in medium 1060 only and lane 4: plasmid DNA w/o benzonase in medium only

Figure 4-figure supplement 5. 1063 1064 1065 1066 1067 sIC formation precedes SARS-CoV-2-IgG response

A) CD16 1069 activation by sICs-vs. S1-ELISA (top panel) and sIC -CD16 activation vs. anti-S-CD16 1070 activation (bottom panel) in one critically ill patient, #C24. B) sIC-CD16 activation vs. S1-1071 ELISA in four individual patients #C13, #C5, #S1 and #C4. Dashed line (black) represents 1072 commercial S1-ELISA-Cut-off level, whereas dashed line (grey) is set to 0

We thank Sophia Ruben and Torsten Schulz from InVivo Bio Tech Services for preparing 726 SARS-CoV-2 (S)-and RBD-coated plates and preparing the SARS-CoV-2 IgG ELISA

Reproducibility of CD16 activation measurements by SARS-CoV-2 specific IgG. Selected 998 sera which were available in sufficient amount from patients with critical (red symbols) or 999 severe (blue symbols) SARS-CoV-2 infection were tested in two independent experiments to 1000show reproducibility and consistency of results. CD16 activation by S-, N-and RBD specific 1001IgG is shown. Statistical tests using a Kolmogorov-Smirnov test indicate no significant 1002 differences. 1003 1004